Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has launched a new research and development facility in New York City, enhancing its R&D capabilities focused on Antibody Radiation Conjugates (ARCs). This facility will be led by Dr. Dale Ludwig and staffed with Ph.D. scientists to accelerate preclinical and clinical development of novel ARCs. The proprietary AWE technology platform is central to these efforts, boasting over 125 patents. The company aims to explore therapeutic combinations and improve targeted conditioning treatments in oncology.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced the activation of University of Louisville and Ochsner Clinic as trial sites for its Phase 1/2 Actimab-A and venetoclax combination trial targeting relapsed or refractory Acute Myeloid Leukemia (R/R AML) patients aged 18 and older. This addition follows a Phase 2 trial where Actimab-A achieved remission rates of 69%. The combination aims to improve response rates and duration while minimizing toxicities. Enrollment for the second dose cohort has started, with expected proof of concept results in 2021.

Actinium Pharmaceuticals (NYSE: ATNM) announced successful completion of the first dosing cohort in its Phase 1 trial combining Actimab-A and venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (AML). All participants cleared safety evaluations, advancing to the second cohort. The trial aims to demonstrate synergy between Actimab-A and venetoclax, potentially enhancing remission rates in R/R AML. Preliminary results from this trial are expected in 2021. Actinium's CD33 program seeks to address significant unmet medical needs in AML treatment.

Actinium Pharmaceuticals (NYSE: ATNM) announced the successful completion of the Phase 1 Actimab-A CLAG-M combination trial at the Medical College of Wisconsin for patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). The third dosing cohort completed treatment with a 0.75 uCi/kg dose, all passing initial safety evaluations. Previous results showed an 86% complete remission rate in the second cohort with 71% achieving negative minimal residual disease status. Full trial results are expected by year-end, indicating potential for advancement depending on FDA clearance.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced that CEO Sandesh Seth will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 2:00 PM EST. The presentation will be available on the company's investor relations website. Actinium is advancing Antibody Radiation-Conjugates aimed at improving conditioning before bone marrow transplants (BMT) with its lead candidate Iomab-B, currently under study in the pivotal Phase 3 SIERRA trial for elderly patients with relapsed or refractory acute myeloid leukemia.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced a 1-for-30 reverse stock split effective August 10, 2020. This decision aims to help the company comply with the NYSE American's minimum price requirements. Post-split, there will be approximately 13,585,268 shares outstanding, and no fractional shares will be issued. The reverse split will also adjust the number of shares issuable upon the exercise of outstanding warrants and stock options. Stockholders will receive information regarding their share ownership from the transfer agent.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced the completion of a public offering, raising approximately $25.0 million by selling 76,923,077 shares at $0.325 per share. Proceeds will fund the ongoing Phase 3 SIERRA trial for its lead candidate, Iomab-B, and support a Biologics License Application to the FDA. Additionally, funds will advance Phase 1 trials for the CD33 program and support general working capital needs. H.C. Wainwright & Co. led the offering with co-placement agents Maxim Group LLC and JonesTrading Institutional Services LLC.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has priced its public offering of 76,923,077 shares at $0.325 per share, expecting gross proceeds of approximately $25 million. The offering is set to close around June 19, 2020. The net proceeds will fund the ongoing Phase 3 SIERRA trial for its product candidate Iomab-B, preparations for a Biologics License Application (BLA), and other developmental initiatives, including Phase 1 trials and general working capital. H.C. Wainwright & Co. is the exclusive placement agent for the offering.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced a proposed public offering of its common stock, subject to market conditions. The company plans to utilize the net proceeds from the offering to advance its pivotal Phase 3 SIERRA trial for Iomab-B, prepare a Biologics License Application to the FDA, and support commercialization efforts. Additionally, funds will be allocated to Phase 1 trials for its CD33 program, research and development, and general working capital. H.C. Wainwright & Co. is the exclusive placement agent for this offering.